ACTG 5381 – Site PI: Dr. Kelvin Mponda
Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampin-Containing TB Treatment: The Hakim Study
ACTG 5282 – Site PI: Dr. Frank Taulo
A Randomized Trial to Compare an HPV Test-And-Treat Strategy To Cytology-Based Strategy For Prevention Of CIN 2+ In HIV-Infected Women
ACTG 5349 – Site PI: Prof. Johnstone Kumwenda & Dr. Kelvin Mponda
Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis
ACTG 5274 – Site PI: Prof. Johnstone Kumwenda
Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)
ACTG 5279 – Site PI: Prof. Johnstone Kumwenda, Dr. N.P.K. Banda, & Dr. Noel Kayange
Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection
ACTG 5263 – Site PI: Dr. Mulinda Nyirenda
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial
ACTG 5264 – Site PI: Dr. Mulinda Nyirenda
As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial
ACTG 5407 / ACTIVE-2D – Site PI: Dr. Kelvin Mponda
Efficacy and Safety of Ensitrelvir in Non-Hospitalized Adults at Standard or High-Risk of Progression to Severe COVID-19: the SCORPIO-HR Phase 3, Randomized, Double-Blind Placebo-Controlled Trial (ACTG 5407)
IMPAACT 2016 – Site PI: Limbika Maliwichi
Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings